구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 19(T2)28z1xx CAR T cells |
Overview Company | Takeda |
Overview Modality | CGT |
Overview Target | Diffuse Large B Cell Lymphoma |
Overview Indication | Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | Targeting Inflammation, Redox Balance, and FOXO1/MIP-2 Signaling |
MoA Biomarker | biomarker |
PK/PD Species | Mouse, HCT-116 and A549 cell lines. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, HCT-116 and A549 cell lines. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.. Evidence remains inconclusive on whether paternal valproate exposure during spermatogenesis is associated with adverse offspring outcomes, with findings lacking beyond Nordic countries. This study aimed to assess the risks of neurodevelopmental disorders (NDDs) and congenital malformations in offspring attributable to paternal… |
Clinical Safety signal | Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.. Evidence remains inconclusive on whether paternal valproate exposure during spermatogenesis is associated with adverse offspring outcomes, with findings lacking beyond Nordic countries. This study aimed to assess the risks of neurodevelopmental disorders (NDDs) and congenital malformations in offspring attributable to paternal… |
Clinical Selected reported efficacy | ORR 17% |
Clinical Reported ORR | 17% |
Clinical Result source | ClinicalTrials.gov NCT03943901 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03943901 |
Preclinical Animal (cat.) | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 19(T2)28z1xx CAR T cells |
Overview Company | Takeda |
Overview Modality | CGT |
Overview Target | Diffuse Large B Cell Lymphoma |
Overview Indication | Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | Targeting Inflammation, Redox Balance, and FOXO1/MIP-2 Signaling |
MoA Biomarker | biomarker |
PK/PD Species | Mouse, HCT-116 and A549 cell lines. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, HCT-116 and A549 cell lines. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.. Evidence remains inconclusive on whether paternal valproate exposure during spermatogenesis is associated with adverse offspring outcomes, with findings lacking beyond Nordic countries. This study aimed to assess the risks of neurodevelopmental disorders (NDDs) and congenital malformations in offspring attributable to paternal… |
Clinical Safety signal | Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.. Evidence remains inconclusive on whether paternal valproate exposure during spermatogenesis is associated with adverse offspring outcomes, with findings lacking beyond Nordic countries. This study aimed to assess the risks of neurodevelopmental disorders (NDDs) and congenital malformations in offspring attributable to paternal… |
Clinical Selected reported efficacy | ORR 17% |
Clinical Reported ORR | 17% |
Clinical Result source | ClinicalTrials.gov NCT03943901 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03943901 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교